NCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
Clinical Trials
19 trialsNCT05960773 2026-03-04
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended
NCT00365053 2018-06-07
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01160458 2018-04-10
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00243074 2018-01-23
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01861301 2016-10-24
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00459862 2015-02-24
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00392444 2014-05-21
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00027703 2014-02-11
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00024271 2014-01-06
Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00030459 2013-08-07
Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01105390 2013-08-02
AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00002475 2013-07-10
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00062283 2013-06-26
Alanosine in Treating Patients With Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00107432 2013-06-05
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006014 2013-06-03
SU5416 in Treating Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00039182 2013-01-24
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025207 2013-01-17
Gefitinib in Treating Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00541073 2011-05-17
Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed